“When setting payment amounts for drugs covered under Medicare Part B, Centers for Medicare & Medicaid Services (CMS) relies on average sales price (ASP) data reported by manufacturers. This report identifies several potential issues with the current ASP reporting process, including (1) the timeliness of manufacturer reporting, (2) the largely manual process used by CMS to collect and analyze manufacturer-reported data, and (3) the legal requirements for manufacturer reporting. Each of these issues introduces the potential for inefficiency and errors.”
Sorry, comments are closed for this post.